Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clonal evolution in chronic myelogenous leukemia.

Jorge Cortes1, Michael E O'Dwyer

  • 1Department of Leukemia, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 428, Houston, TX 77030, USA. jcortes@mdanderson.org

Hematology/Oncology Clinics of North America
|July 24, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants.

Blood·2013
Same author

Proteomic profiling identifies distinct protein patterns in acute myelogenous leukemia CD34+CD38- stem-like cells.

PloS one·2013
Same author

Clinical activity of ponatinib in patients with chronic myeloid leukemia in chronic phase with e1a2 transcripts.

Haematologica·2013
Same author

Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research.

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation·2013
Same author

HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia.

Cancer·2013
Same author

Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents.

Leukemia & lymphoma·2013
Same journal

Palliative Therapy for Liver and Biliary Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Ablative Therapies for Liver Tumors.

Hematology/oncology clinics of North America·2026
Same journal

Pathology of Liver and Biliary Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Minimally Invasive Surgery for Liver and Biliary Tract Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Surgical Considerations for Primary Liver Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Systemic Therapy for Biliary and Liver Neoplasms: Chemotherapy and Immunotherapy.

Hematology/oncology clinics of North America·2026
See all related articles

Clonal evolution in chronic myelogenous leukemia (CML) is linked to disease progression. Routine cytogenetic analysis is crucial for imatinib-treated CML patients to monitor chromosomal changes.

Area of Science:

  • Hematology
  • Oncology
  • Genetics

Background:

  • Clonal evolution (CE) is associated with disease progression in chronic myelogenous leukemia (CML).
  • CE frequency increases with CML stage, from 30% in accelerated phase to 80% in blast crisis.
  • CE is considered a defining feature of accelerated-phase CML, though outcomes vary.

Purpose of the Study:

  • To investigate the role of clonal evolution in CML progression.
  • To highlight the occurrence of chromosomal abnormalities in imatinib-treated patients.
  • To emphasize the importance of routine cytogenetic analysis in CML management.

Main Methods:

  • Review of existing literature on clonal evolution in CML.
  • Analysis of cytogenetic data from CML patients, including those treated with imatinib.

Related Experiment Videos

  • Assessment of the incidence and implications of chromosomal abnormalities.

    • Main Results:

    • Clonal evolution is a marker of disease progression in CML.
    • Chromosomal abnormalities in Ph-negative metaphases occur in 2-17% of imatinib-treated patients.
    • The precise incidence and long-term implications of these abnormalities require further study.

    Conclusions:

    • Routine cytogenetic analysis is essential for CML patients on imatinib.
    • Understanding these chromosomal changes can improve CML pathogenesis insights.
    • Further research is needed to optimize long-term CML treatment strategies.